|The IRF9 irf9 (Catalog #MBS9218694) is a Blocking Peptide and is intended for research purposes only. The product is available for immediate purchase.
The IRF9 irf9 product has the following accession number(s) (GI #266392) (NCBI Accession #Q00978.1) (Uniprot Accession #Q00978). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Transcription factor that mediates signaling by type I IFNs (IFN-alpha and IFN-beta). Following type I IFN binding to cell surface receptors, Jak kinases (TYK2 and JAK1) are activated, leading to tyrosine phosphorylation of STAT1 and STAT2. IRF9/ISGF3G associates with the phosphorylated STAT1:STAT2 dimer to form a complex termed ISGF3 transcription factor, that enters the nucleus. ISGF3 binds to the IFN stimulated response element (ISRE) to activate the transcription of interferon stimulated genes, which drive the cell in an antiviral state.
Cellular Location: Cytoplasm. Nucleus. Note: Translocated into the nucleus upon activation by IFN-alpha/beta. The following patways have been known to be associated with this gene. Brain Diseases, Carcinoma, Hepatocellular, Cardiovascular Diseases, Cell Transformation, Neoplastic, Fibrosis, Heart Diseases, Inflammation, Liver Diseases, Lung Diseases, Necrosis are some of the diseases may be linked to IRF9 Antibody (N-term) Blocking peptide. Blood, Bone, Brain, Kidney, Liver, Lung, Muscle, Skin, Spleen, Vascular tissues are correlated with this protein. IRF9 also interacts with the following gene(s): CREBBP, IFNAR2, IRF1, ISG15, ISG20, JAK1, MX1, STAT1, STAT2, TYK2.